Patients with symptoms of anxiety significantly more likely to use psychotropic medications after hospital discharge
No similar findings seen for middle-aged women
Findings seen for COVID-19 infection, hospitalization, and mortality
Patients with schizophrenia, mood disorders, anxiety disorders have increased odds of COVID-19 mortality
Relative risks for mortality significantly reduced for any SSRI, fluoxetine, and fluoxetine or fluvoxamine
2015 to 2019 saw increase in all-cause mortality rates, mortality for drug/alcohol poisoning
Two-year trajectory of depression symptoms significantly linked to cancer survival; association for anxiety not significant
COVID-19 standardized mortality rates were elevated across nine psychiatric conditions including learning disabilities, eating disorders
Risk for loss was 1.1 to 4.5 times higher among children of racial/ethnic minorities compared with non-Hispanic Whites
Fatal opioid overdoses four times more likely in the two days after hospital discharge